NSAIDs in COVID-19, friend or foe?

  • Reham Mahrous
  • Amr Abdelnasser
  • Raghda Fouda
  • Mohamed Abd Al Moniem Morsy
  • Mohamed Ahmed Ibrahim
  • Omnia Mandour
Keywords: Nill

Abstract

At the beginning of COVID-19 pandemic the use of NSAIDS was avoided. This was because the previous studies suggesting that NSAIDs may be linked to an increased risk of lower respiratory tract infection consequences. Later on studies involved the patients who used NSAIDs for some chronic conditions and showed no additional harm among these patients. Then many studied assessed the benefit of using NSAIDs in COVID-19 patients for management of pain and fever and showed no additional risk among these patients.

Key words:

Citation: Mahrous R, Abdelnasser A, Fouda R, Morsy MAM, Ibrahim MA, Mandour O. NSAIDs in COVID-19, friend or foe? Anaesth. pain intensive care 2022;26(4):427-429; DOI: 10.35975/apic.v26i4.1942

Received: May 29, 2022; Reviewed:  June 06, 2022, 2022; Accepted:  June 06, 2022

 

Author Biographies

Reham Mahrous

MD, Department of Anesthesia, surgical ICU and pain management, Cairo University, Egypt

Amr Abdelnasser

MD, Department of Anesthesia, surgical ICU and pain management, Cairo University, Egypt

Raghda Fouda

University of Irvine California, USA

Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Egypt

Mohamed Abd Al Moniem Morsy

MD, Department of Anesthesia, surgical ICU and pain management, Cairo University, Egypt

Mohamed Ahmed Ibrahim

MD, Department of Anesthesia, surgical ICU and pain management, Cairo University, Egypt

Omnia Mandour

MD, Department of Anesthesia, surgical ICU and pain management, Cairo University, Egypt

Published
08-11-2022
How to Cite
Mahrous, R., Abdelnasser, A., Fouda, R., Moniem Morsy, M., Ibrahim, M., & Mandour, O. (2022). NSAIDs in COVID-19, friend or foe?. Anaesthesia, Pain & Intensive Care, 26(4), 427-429. https://doi.org/10.35975/apic.v26i4.1942
Section
Editorial Views

Most read articles by the same author(s)